RHEI names Dr Geert Cauwenbergh CEO
This article was originally published in Scrip
RHEI Pharmaceuticals (US) has appointed Dr Geert Cauwenbergh chief executive officer. He succeeds Joos Horsten, who died recently. In February, Dr Cauwenbergh founded Phases123, a company focused on identifying healthcare technology platforms and emerging healthcare companies. In 2001, he founded Barrier Therapeutics.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.